A Randomised, Double-blind, Parallel-group, Placebo Controlled Induction Trial to Assess the Clinical Efficacy and Safety of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

NCT01203631 Phase 2 COMPLETED

This trial is conducted in Europe and North America. The aim of the trial is to assess disease activity and safety in subjects with moderately to severely active Crohn's disease (CD) when treated with NNC 0142-0000-0002.

Details

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 2
Status	COMPLETED
Enrolment	78
Start date	2011-02
Completion	2013-05

Conditions

• Inflammation
• Crohn's Disease

Interventions

• NNC 0142-0000-0002
• Placebo

Primary outcomes

• Change in disease activity assessed by CDAI (Crohn's disease activity index) — From baseline to week 4

Countries

United States, Belgium, Canada, France, Hungary, Israel, Poland, Russia